University of Pittsburgh

Baxter International Inc.

Baxter Healthcare Sa

Duquesne University

Larry R. Brown

Terrence L. Scott

Nick Giannoukakis

Vered Bisker-Leib

Jennifer Machen

Massimo M Trucco

Larry Richard Brown

Larry R Brown

Kimberly A Gillis

Paul David Robbins

Terrence L Scott

Debra Lafreniere

Wilson S Meng

Lina Lu

Massimo Trucco

Deborah Lafreniere

Larry L Brown

Vered Bisker-Lieb

The present invention relates to tolerogenic mammalian dendritic cells (iDCs) and methods for the production of tolerogenic DCs. In addition, the present invention provides methods for administration of tolerogenic dendritic cells as well as particles containing oligonucleotides to mammalian subjects. Enhanced tolerogenicity in a host can be useful for treating inflammatory and autoimmune related diseases, such as type 1 diabetes.

Microsphere-based delivery and ex vivo manipulation of dendritic cells for autoimmune therapies

Particle formulations are disclosed that include polymeric particles containing a small molecule drug and a high molecular weight therapeutic protein. Methods of making and using the particle formulations also are disclosed. These particle formulations are of use to treat an autoimmune disease, such as diabetes, or an inflammatory disease.

Particle formulations of all-trans retinoic acid and transforming growth factor beta for the treatment of type 1 diabetes mellitus

AS-oligonucleotides are delivered in microsphere form in order to induce dendritic cell tolerance, particularly in the non-obese-diabetic (NOD) mouse model. The microspheres incorporate antisense (AS) oligonucleotides. A process includes using an antisense approach to prevent an autoimmune diabetes condition in NOD mice in vivo and in situ. The oligonucleotides are targeted to bind to primary transcripts CD40, CD80, CD86 and their combinations.

Delivery of AS-oligonucleotide microspheres to induce dendritic cell tolerance for the treatment of autoimmune type 1 diabetes

AS-oligonucleotides are delivered in microsphere form in order to induce dendritic cell tolerance, particularly in the non-obese-diabetic (NOD) mouse model. The microspheres incorporate antisense (AS) oligonucleotides. A process includes using an antisense approach to reverse an autoimmune diabetes condition in NOD mice in vivo. The oligonucleotides are targeted to bind to primary transcripts CD40, CD80, CD86 and their combinations.

Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes

A method is provided that includes using an antisense approach to reverse and/or delay an autoimmune diabetes condition in vivo. The oligonucleotides are targeted to bind to primary transcripts CD40, CD80, CD86 and their combinations.

The present invention relates to tolerogenic mammalian dendritic cells (DCs) and methods for the production of the tolerogenic DCs. In addition, the present invention provides a method for enhancing tolerogenicity in a host comprising administering the tolerogenic mammalian DCs of the present invention to the host. The tolerogenic DCs of the present invention comprise an oligodeoxyribonucleotide (ODN) which has one or more NF-&#x3ba;B binding sites. The tolerogenic DCs of the present invention may further comprise a viral vector, and preferably an adenoviral vector, which does not affect the tolerogenicity of the tolerogenic DCs when present therein. Enhanced tolerogenicity in a host is useful for prolonging foreign graft survival and for treating inflammatory related diseases, such as autoimmune diseases.

Use of tolerogenic dendritic cells for enhancing tolerogenicity in a host and methods for making the same

Growing community of inventors

Coraopolis, PA, United States of America

Nick Giannoukakis